Piribedil (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Piribedil" in English language version.

refsWebsite

Global rank English rank

11nih.gov

4^th place

9doi.org

2^nd place

8semanticscholar.org

11^th place

8^th place

1europa.eu

68^th place

117^th place

1aspetjournals.org

6,663^rd place

5,792^nd place

1servier.com

low place

1web.archive.org

1^st place

aspetjournals.org

jpet.aspetjournals.org

Millan MJ, Cussac D, Milligan G, Carr C, Audinot V, Gobert A, et al. (June 2001). "Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization". The Journal of Pharmacology and Experimental Therapeutics. 297 (3): 876–887. PMID 11356907.

doi.org

Gobert A, Di Cara B, Cistarelli L, Millan MJ (April 2003). "Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors". The Journal of Pharmacology and Experimental Therapeutics. 305 (1): 338–346. doi:10.1124/jpet.102.046383. PMID 12649387. S2CID 29234876.
Gierski F, Peretti CS, Ergis AM (January 2007). "Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 31 (1): 262–268. doi:10.1016/j.pnpbp.2006.06.017. PMID 16876301. S2CID 792757.
Peretti CS, Gierski F, Harrois S (November 2004). "Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil". Psychopharmacology. 176 (2): 175–181. doi:10.1007/s00213-004-1869-8. PMID 15138753. S2CID 24952829.
Evidente VG (May 2001). "Piribedil for restless legs syndrome: a pilot study". Movement Disorders. 16 (3): 579–581. doi:10.1002/mds.1104. PMID 11391766. S2CID 39995329.
Tschopp L, Salazar Z, Gomez Botello MT, Roca CU, Micheli F (2010). "Impulse control disorder and piribedil: report of 5 cases". Clinical Neuropharmacology. 33 (1): 11–13. doi:10.1097/WNF.0b013e3181c4ae2e. PMID 19959959. S2CID 30844295.
Gouraud A, Millaret A, Descotes J, Vial T (2011). "Piribedil-induced sleep attacks in patients without Parkinson disease: a case series". Clinical Neuropharmacology. 34 (3): 104–107. doi:10.1097/WNF.0b013e31821f0d8b. PMID 21586915. S2CID 22169346.
Arnsten AF, Murphy B, Merchant K (October 2000). "The selective dopamine D4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys". Neuropsychopharmacology. 23 (4): 405–10. doi:10.1016/S0893-133X(00)00133-0. PMID 10989267. S2CID 16143246.
Nagaraja D, Jayashree S (September 2001). "Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment". The American Journal of Psychiatry. 158 (9): 1517–9. doi:10.1176/appi.ajp.158.9.1517. PMID 11532743.
Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 805–814. doi:10.1124/jpet.102.039875. PMID 12388667. S2CID 35238120.

europa.eu

ema.europa.eu

"Active substance: piribedil" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 26 November 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Millan MJ, Cussac D, Milligan G, Carr C, Audinot V, Gobert A, et al. (June 2001). "Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization". The Journal of Pharmacology and Experimental Therapeutics. 297 (3): 876–887. PMID 11356907.
Gobert A, Di Cara B, Cistarelli L, Millan MJ (April 2003). "Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors". The Journal of Pharmacology and Experimental Therapeutics. 305 (1): 338–346. doi:10.1124/jpet.102.046383. PMID 12649387. S2CID 29234876.
Gierski F, Peretti CS, Ergis AM (January 2007). "Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 31 (1): 262–268. doi:10.1016/j.pnpbp.2006.06.017. PMID 16876301. S2CID 792757.
Bochkarev VK, Faĭzulloev AZ, Avedisova AS (2005). "[Efficacy of pronoran in age-related memory impairment]". Zhurnal Nevrologii I Psikhiatrii imeni S.S. Korsakova. 105 (2): 46–50. PMID 15792142.
Peretti CS, Gierski F, Harrois S (November 2004). "Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil". Psychopharmacology. 176 (2): 175–181. doi:10.1007/s00213-004-1869-8. PMID 15138753. S2CID 24952829.
Evidente VG (May 2001). "Piribedil for restless legs syndrome: a pilot study". Movement Disorders. 16 (3): 579–581. doi:10.1002/mds.1104. PMID 11391766. S2CID 39995329.
Tschopp L, Salazar Z, Gomez Botello MT, Roca CU, Micheli F (2010). "Impulse control disorder and piribedil: report of 5 cases". Clinical Neuropharmacology. 33 (1): 11–13. doi:10.1097/WNF.0b013e3181c4ae2e. PMID 19959959. S2CID 30844295.
Gouraud A, Millaret A, Descotes J, Vial T (2011). "Piribedil-induced sleep attacks in patients without Parkinson disease: a case series". Clinical Neuropharmacology. 34 (3): 104–107. doi:10.1097/WNF.0b013e31821f0d8b. PMID 21586915. S2CID 22169346.
Arnsten AF, Murphy B, Merchant K (October 2000). "The selective dopamine D4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys". Neuropsychopharmacology. 23 (4): 405–10. doi:10.1016/S0893-133X(00)00133-0. PMID 10989267. S2CID 16143246.
Nagaraja D, Jayashree S (September 2001). "Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment". The American Journal of Psychiatry. 158 (9): 1517–9. doi:10.1176/appi.ajp.158.9.1517. PMID 11532743.
Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 805–814. doi:10.1124/jpet.102.039875. PMID 12388667. S2CID 35238120.

semanticscholar.org

api.semanticscholar.org

Gobert A, Di Cara B, Cistarelli L, Millan MJ (April 2003). "Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors". The Journal of Pharmacology and Experimental Therapeutics. 305 (1): 338–346. doi:10.1124/jpet.102.046383. PMID 12649387. S2CID 29234876.
Gierski F, Peretti CS, Ergis AM (January 2007). "Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 31 (1): 262–268. doi:10.1016/j.pnpbp.2006.06.017. PMID 16876301. S2CID 792757.
Peretti CS, Gierski F, Harrois S (November 2004). "Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil". Psychopharmacology. 176 (2): 175–181. doi:10.1007/s00213-004-1869-8. PMID 15138753. S2CID 24952829.
Evidente VG (May 2001). "Piribedil for restless legs syndrome: a pilot study". Movement Disorders. 16 (3): 579–581. doi:10.1002/mds.1104. PMID 11391766. S2CID 39995329.
Tschopp L, Salazar Z, Gomez Botello MT, Roca CU, Micheli F (2010). "Impulse control disorder and piribedil: report of 5 cases". Clinical Neuropharmacology. 33 (1): 11–13. doi:10.1097/WNF.0b013e3181c4ae2e. PMID 19959959. S2CID 30844295.
Gouraud A, Millaret A, Descotes J, Vial T (2011). "Piribedil-induced sleep attacks in patients without Parkinson disease: a case series". Clinical Neuropharmacology. 34 (3): 104–107. doi:10.1097/WNF.0b013e31821f0d8b. PMID 21586915. S2CID 22169346.
Arnsten AF, Murphy B, Merchant K (October 2000). "The selective dopamine D4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys". Neuropsychopharmacology. 23 (4): 405–10. doi:10.1016/S0893-133X(00)00133-0. PMID 10989267. S2CID 16143246.
Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 805–814. doi:10.1124/jpet.102.039875. PMID 12388667. S2CID 35238120.

servier.com

TRIVASTAL Retard 50 (piribedil) Prescribing Information, Servier Laboratories, April 2008. [1] Archived 19 December 2012 at the Wayback Machine

web.archive.org

TRIVASTAL Retard 50 (piribedil) Prescribing Information, Servier Laboratories, April 2008. [1] Archived 19 December 2012 at the Wayback Machine